Could we soon have biomarkers for early pre-symptomatic Alzheimer’s disease?

Takeaway

  • A large harmonized database of biomarkers of early pre-symptomatic Alzheimer’s disease (AD) may soon be available.

Why this matters

    It is well-known that neurological damage in AD occurs long before the onset of overt symptoms. A better understanding of this preclinical stage of disease, and in particular the availability of biomarkers for tracking early pre-symptomatic changes, could facilitate research into disease prevention with anti-AD therapies.